arrow
R

Roberto Moretto

azienda ospedaliero-universitaria pisana
H指数:28
被引数:3,230

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Re-treatment with panitumumab followed by regorafenib versus the reverse sequence in chemorefractory metastatic colorectal cancer patients with RAS and BRAF wild-type circulating tumor DNA: the PARERE study by GONO

帕尼单抗(panitumumab)再治疗随后使用瑞戈非尼(regorafenib)与相反顺序在RAS和 BRAF野生型循环肿瘤DNA的化学耐药性转移性结直肠癌患者中的比较:GONO进行的PARERE研究

2025-10-180
OAAI
FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: an individual patient data-based pooled analysis of randomized trials

FOLFOXIRI/bevacizumab与双药/bevacizumab作为不可切除的肝-only、右侧和/或RAS或BRAF突变转移性结直肠癌初始治疗的比较:一项基于个体患者数据的随机试验合并分析

2025-08-150
PRE
The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studies

FOLFOXIRI和FOLFOX/FOLFIRI两种一线方案,无论是否联合贝伐珠单抗,其相对剂量强度均会影响转移性结直肠癌患者的预后:TRIBE和TRIBE2研究的合并分析

2025-06-010
PRE
Hepatectomy v°ersus systemic therapy for liver-limited BRAF V600E-mutated colorectal liver metastases: multicentre retrospective study
2024-07-250
PRE
Predicting early recurrence after resection of initially unresectable colorectal liver metastases: the role of baseline and pre-surgery clinical, radiological and molecular factors in a real-life multicentre experience
2024-04-014
OAAI
ShorTrip Trial: A Prospective, Multicentric Phase II Single-Arm Trial of Short-Course Radiotherapy Followed by Intensified Consolidation Chemotherapy With the Triplet FOLFOXIRI as Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer
2023-09-010
PRE
Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study
2023-04-2118
OAAI
Trop-2 and Nectin-4 immunohistochemical expression in metastatic colorectal cancer: searching for the right population for drugs' development
2023-02-0910
OA
Demystifying BRAF Mutation Status in Colorectal Liver Metastases A Multi-institutional, Collaborative Approach to 6 Open Clinical Questions

揭示结直肠肝转移中BRAF突变状态的多机构,协作方法解决6个开放性临床问题

2022-12-0112
PRE
Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?

FOLFOXIRI和贝伐单抗在BRAFV600E-mutated转移性结直肠癌患者中的先期获益: 原发肿瘤位置重要吗?

2022-06-039
OA
Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience
2022-06-0121
OAAI